Remove 2024 Remove Adverse Reactions Remove Vaccines
article thumbnail

FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia

Pharmacy Times

Common adverse reactions included gastrointestinal issues, with a low discontinuation rate due to adverse drug reactions. November 11, 2024. OLC, a lanthanum-based phosphate binder, showed efficacy and tolerability in a phase 2 trial, with most patients achieving target serum phosphate levels. News release.

FDA 73
article thumbnail

Mitomycin Intravesical Solution Receives FDA Approval for Non-Muscle Invasive Bladder Cancer

Pharmacy Times

3 The safety profile was favorable with the most common adverse effect (AE) being increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria.

FDA 65
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

Pharmacy Times

While no new adverse reactions were observed in this study, higher rates of hypersensitivity and infusion-related reactions were observed. November 8, 2024. July 2, 2024. A total of 1736 individuals across 8 countries were included, demonstrating slowed clinical progression at 76 weeks. July 9, 2025. Mayo Clinic.

article thumbnail

Every Claim You Make, Every Step You Take…CVM Will Be Watching You

The FDA Law Blog

Elanco is the manufacturer of recently approved Zenrelia (ilunocitinib tablets) (September 2024), which is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. Further, information presented on the adverse reaction data was inconsistent with the PI.

article thumbnail

Alembic Pharmaceuticals acquires UTILITY therapeutics

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? In April 2024, Pivya received approval from the US Food and Drug Administration (FDA) for uUTIs. The most common adverse reactions are diarrhoea, nausea, vulvovaginal candidiasis, genital pruritus and headache. ” Pivya has been proven safe in three studies.

article thumbnail

First chikungunya vaccine approved

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved Valneva SE’s IXCHIQ ® , the first chikungunya vaccine to be authorised in the world. The single-dose, live-attenuated vaccine is indicated for preventing chikungunya virus disease in individuals over 18 years old who are at increased risk of contracting the virus.